Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
Memorial Sloan Kettering Cancer Center · Cornell University · +18 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
450
total citations
- FWCI
- 97.42
- Percentile
- 100%
- References
- 22
Citations per year
Authors
20- YYYelena Y. JanjigianCorresponding
Memorial Sloan Kettering Cancer Center, Cornell University
- AKAkihito Kawazoe
National Cancer Center Hospital East
- YBYuxian Bai
Harbin Medical University, Third Affiliated Hospital of Harbin Medical University
- JXJianming Xu
Chinese PLA General Hospital
- SLSara Lonardi
Istituto Oncologico Veneto, Istituti di Ricovero e Cura a Carattere Scientifico
Topics & keywords
Topics
Keywords
- Medicine
- Gastro-
- Internal medicine
- Trastuzumab
- Pembrolizumab
- Placebo
- Chemotherapy
- Interim
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.